Literature DB >> 11083261

Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study.

L R Spiegel1, R Schneider, B A Lang, N Birdi, E D Silverman, R M Laxer, D Stephens, B M Feldman.   

Abstract

OBJECTIVE: To examine the ability of a previously described set of criteria to predict poor functional outcome in a large, multicenter cohort of children with systemic-onset juvenile rheumatoid arthritis (JRA).
METHODS: All children who were diagnosed with systemic-onset JRA since 1980 at the Hospital for Sick Children (Toronto), since 1983 at the Isaac Walton Killam Hospital for Children (Halifax), and since 1981 at the Children's Hospital of Eastern Ontario (Ottawa) were evaluated. Patients were included in the study if they had been evaluated clinically within 6 months of diagnosis and had been followed up for at least 2 years. Patients were divided into 4 cohorts according to their length of followup: 2-4 years, 4-7 years, 7-10 years, and >10 years. Using previously described criteria for destructive arthritis in children with systemic-onset JRA, the patients were classified as either high risk or low risk for poor functional outcome based on the data from their 6-month visit. High-risk patients had active systemic disease (persistent fever or corticosteroid requirement for control of systemic disease) and a platelet count > or =600 x 10(9)/liter. Poor outcome was defined as moderate or severe disability (defined as a score of > or =0.75 on the Childhood Health Assessment Questionnaire) or disease-associated death.
RESULTS: Among 122 eligible patients with systemic-onset JRA, we were able to contact 111 (91%) for outcome data. The mean followup period was 7.7 years (SD 3.7). The mean age at outcome assessment was 13.5 years (SD 5.3). There were 51 boys and 60 girls. Twenty-four patients (22%) had moderate-to-severe disability and 2 patients died; these 26 patients were considered to have had a poor outcome. We could determine risk classification for 104 patients. Twenty-four patients (23%) met the criteria for high risk at the 6-month visit. Overall, the risk of a poor functional outcome was significantly higher in the high-risk group (relative risk 3.3, 95% confidence interval [95% CI] 1.73-6.43, P = 0.0004). This risk was most marked in the cohort with > 10 years of followup (relative risk 4.3, 95% CI 1.82-10.29, P = 0.006).
CONCLUSION: The presence of active systemic disease at 6 months, as characterized by fever or the need for corticosteroids, and thrombocytosis strongly predicted the development of a poor functional outcome in these patients. This was especially apparent with longterm followup. Our study validates the previously developed prognostic criteria for systemic-onset JRA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083261     DOI: 10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  37 in total

Review 1.  Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.

Authors:  Sathish Kumar
Journal:  Indian J Pediatr       Date:  2016-02-26       Impact factor: 1.967

Review 2.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.

Authors:  Hatice Ezgi Baris; Edwin Anderson; Betul Sozeri; Fatma Dedeoglu
Journal:  Clin Rheumatol       Date:  2018-09-20       Impact factor: 2.980

4.  Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Turkish population and in Turkish patients with juvenile rheumatoid arthritis.

Authors:  A Ruhi Ozyürek; Dolunay Gürses; Zülal Ulger; Ertürk Levent; A Rahmi Bakiler; Afig Berdeli
Journal:  Clin Rheumatol       Date:  2006-07-12       Impact factor: 2.980

5.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

6.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

7.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

8.  Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Mark Gorelik; Ndate Fall; Mekibib Altaye; Michael G Barnes; Susan D Thompson; Alexei A Grom; Raphael Hirsch
Journal:  J Rheumatol       Date:  2013-05-15       Impact factor: 4.666

Review 9.  The management of osteoporosis in children.

Authors:  L M Ward; V N Konji; J Ma
Journal:  Osteoporos Int       Date:  2016-04-28       Impact factor: 4.507

10.  Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.

Authors:  Kimme L Hyrich; Sham D Lal; Helen E Foster; Judith Thornton; Navid Adib; Eileen Baildam; Janet Gardner-Medwin; Lucy R Wedderburn; Alice Chieng; Joyce Davidson; Wendy Thomson
Journal:  Rheumatology (Oxford)       Date:  2009-11-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.